STOCK TITAN

Brainstorm Cell Theraputc (BCLI) Stock Price, News & Analysis

BCLI OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
93 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+29.9% close of August 18, 2026
1-year change
+54.8% closing prices, November 14, 2025 to November 16, 2026
1-month change
+21.9% closing prices, October 16, 2026 to November 16, 2026

Company Description

BrainStorm Cell Therapeutics Inc. (BCLI) is a biotechnology company focused on developing autologous adult stem cell therapies for debilitating neurodegenerative diseases. According to company disclosures and recent press releases, BrainStorm’s work centers on its proprietary NurOwn® technology platform, which uses a patient’s own mesenchymal stem cells (MSCs) to generate neurotrophic factor-secreting cells (MSC‑NTF cells). These cells are designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection in disorders such as amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS).

BrainStorm’s common stock trades under the symbol BCLI. A Form 25 filed by The Nasdaq Stock Market LLC on October 9, 2025, documents the removal of BrainStorm Cell Therapeutics Inc. from listing on Nasdaq. Subsequent company communications state that the shares are quoted on the OTCQB Venture Market, and an 8‑K dated November 14, 2025, and another dated January 9, 2026, list BCLI as trading on the OTCQB.

NurOwn® platform and core therapeutic focus

The company describes NurOwn® (autologous MSC‑NTF cells) as an investigational therapeutic approach that targets disease pathways important in neurodegenerative disorders. MSC‑NTF cells are produced from autologous, bone marrow‑derived MSCs that are expanded and differentiated ex vivo under patented conditions. These conditions induce the cells to secrete high levels of neurotrophic factors (NTFs) and immunomodulatory cytokines. BrainStorm states that these autologous MSC‑NTF cells are designed to deliver multiple NTFs and immunomodulatory cytokines directly to sites of damage, with the goal of eliciting a desired biological effect and ultimately slowing or stabilizing disease progression.

According to multiple company press releases, NurOwn® is BrainStorm’s lead investigational therapy for ALS. The company reports that NurOwn has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for ALS. BrainStorm has completed a Phase 3 trial in ALS (ClinicalTrials.gov ID NCT03280056) and is preparing a Phase 3b trial, referred to as the ENDURANCE study, under a Special Protocol Assessment (SPA) agreement with the FDA.

Clinical development in ALS

BrainStorm’s disclosures describe a multi‑stage clinical program in ALS:

  • A completed Phase 3 ALS trial (NCT03280056), which generated clinical and biomarker data.
  • Plans for a Phase 3b ENDURANCE trial, designed in collaboration with the FDA under an SPA and intended to enroll approximately 200 participants with early‑stage ALS. Company press releases explain that the trial includes a 24‑week randomized, double‑blind, placebo‑controlled period followed by a 24‑week open‑label extension in which all participants receive NurOwn. The primary efficacy endpoint is the change from baseline to week 24 on the ALS Functional Rating Scale‑Revised (ALSFRS‑R). BrainStorm states that successful completion of the double‑blind portion (Part A) is expected to generate data to support a potential Biologics License Application (BLA).
  • An Expanded Access Program (EAP) for ALS participants who previously completed the Phase 3 trial. In a June 16, 2025 press release, BrainStorm reports survival data from 10 EAP participants, noting that 9 of 10 survived more than five years from ALS symptom onset, with a median survival of 6.8 years. The company contrasts this with published estimates indicating that approximately 10% of individuals with ALS survive beyond five years, and states that the probability of observing such extended survival purely by chance is extremely low.

BrainStorm also highlights additional analyses from its ALS program, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the so‑called “Floor Effect” in advanced ALS, which it describes as a critical challenge in measuring clinical outcomes. The company notes that these findings have been presented at scientific meetings and published in peer‑reviewed journals.

Additional indications and research platforms

Beyond ALS, BrainStorm reports that it has completed a Phase 2 open‑label multicenter trial (NCT03799718) of MSC‑NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. The company also states that it is advancing a proprietary, allogeneic exosome‑based platform designed to deliver therapeutic proteins and nucleic acids. According to company press releases, BrainStorm has received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering this exosome technology, which it describes as strengthening its intellectual property portfolio in regenerative medicine.

Regulatory and community engagement

BrainStorm’s communications emphasize ongoing engagement with regulatory authorities and the ALS community. The company reports:

  • FDA clearance to initiate the Phase 3b NurOwn trial in ALS, with the trial design agreed under an SPA.
  • Submission of an Investigational New Drug (IND) amendment for NurOwn to the FDA, described as an important step toward initiating the Phase 3b study.
  • Recognition of a Citizen Petition submitted by representatives of the ALS community, requesting renewed regulatory review of NurOwn data. BrainStorm states that it did not participate in drafting or submitting the petition but views the FDA’s consideration of the petition as an opportunity for a fresh evaluation of the evidence.

Company press releases also note participation by BrainStorm’s leadership and scientific team in professional meetings, including presentations at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting and the ALS Drug Development Summit, where the company has discussed pharmacogenomic findings and cerebrospinal fluid biomarker pathways associated with NurOwn treatment.

Manufacturing and partnerships

To support its clinical programs, BrainStorm describes several manufacturing‑related arrangements. In May 2025, the company announced a Letter of Intent (LOI) with Minaris Advanced Therapies, a contract development and manufacturing organization specializing in cell and gene therapies, to manufacture NurOwn for an upcoming clinical trial at a facility in Allendale, New Jersey. BrainStorm states that this collaboration is intended to initiate technology transfer of NurOwn and enhance U.S.‑based manufacturing capabilities for its planned multicenter Phase 3b ALS trial.

The company also references a collaboration with Pluri Inc. in Israel to contribute to the production of clinical trial material, describing these relationships as part of a broader effort to build a flexible manufacturing network for NurOwn.

Capital structure, financing, and listing status

BrainStorm’s SEC filings provide insight into its capital structure and financing activities. An 8‑K filed June 25, 2025, notes that stockholders approved amendments to the company’s 2014 Stock Incentive Plan and 2014 Global Share Option Plan, increasing the shared pool of common shares available for issuance under these plans. Subsequent 8‑K filings dated November 6, 2025, November 14, 2025, and January 9, 2026, describe multiple promissory notes and convertible promissory notes issued to institutional investors, including Vanquish Funding Group Inc., Labrys Fund II, L.P., Quick Capital, LLC, and Auctus Fund, LLC. These notes include original issue discounts, specified maturity dates, scheduled amortization payments, and conversion features that may allow holders to convert outstanding amounts into shares of common stock upon certain events, subject to beneficial ownership limitations and other terms.

The Form 25 dated October 9, 2025, filed by Nasdaq Stock Market LLC, confirms the removal of BrainStorm Cell Therapeutics Inc.’s common stock from listing and registration on Nasdaq. In a July 17, 2025 press release, the company states that the delisting resulted from non‑compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum shareholder equity, and that BrainStorm obtained approval for its common stock to be quoted on the OTCQB Venture Market under the same symbol, BCLI.

Business model context

Based on the company’s own descriptions, BrainStorm’s activities are concentrated in clinical‑stage development of cell‑based therapeutics for neurodegenerative diseases. Its primary assets are its NurOwn autologous MSC‑NTF platform, associated clinical data and regulatory designations in ALS, its early‑stage work in progressive MS, and its allogeneic exosome‑based technology platform. Revenue‑generating commercial products are not described in the provided materials; instead, disclosures focus on clinical trials, regulatory interactions, intellectual property, and financing transactions.

Key points for BCLI stock research

  • Sector and industry: BrainStorm is classified in Biological Product (except Diagnostic) Manufacturing within the broader manufacturing/biotechnology space.
  • Lead program: NurOwn autologous MSC‑NTF cells for ALS, with Orphan Drug designations from FDA and EMA, a completed Phase 3 trial, and a planned Phase 3b trial under an SPA.
  • Additional programs: Phase 2 open‑label multicenter trial completed in progressive MS; development of an allogeneic exosome‑based platform for delivery of therapeutic proteins and nucleic acids.
  • Listing status: Common stock delisted from Nasdaq via Form 25 on October 9, 2025; company reports quotation on the OTCQB Venture Market under symbol BCLI.
  • Financing: Use of promissory and convertible promissory notes with institutional investors, and equity incentive plans as described in SEC filings.

Stock Performance

$0.9500
-4.04%
-0.0400
Last updated: November 16, 2026 at 16:00
+54.8%
Performance 1 year
$10.5M

Brainstorm Cell Theraputc (BCLI) closed at $0.9500 on November 16, 2026. Over the past 12 months, the price has gained 54.8%.

See what a $1,000 investment in BCLI would be worth today

Average down calculator for BCLI

BCLI Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Brainstorm Cell Theraputc has 10 recent news articles, with the latest published today. Of the recent coverage, 6 articles coincided with positive price movement and 1 with negative movement. Key topics include earnings, management, private placement. View all BCLI news →

Financial Highlights

Brainstorm Cell Theraputc reported diluted earnings per share of -$1.11 in FY2025. The current ratio was 0.03, measuring current assets divided by current liabilities.

—
Revenue (FY2025)
—
Net Income (FY2025)
—
Operating Cash Flow

Upcoming Events

FEB
13
February 13, 2031 Financial

Warrant expiration

120% warrant coverage exercisable at $1.00; five-year expiry per 8-K
MAY
11
May 11, 2031 Financial

Warrant expiry

Warrants from May 11, 2026 private placement expire; $1.45 strike; 120% coverage; potential dilution for BCLI investors.
MAY
18
May 18, 2031 Financial

Warrant expiry

Warrants from May 18, 2026 private placement expire; $1.45 strike; 120% coverage; potential dilution for BCLI investors.

Brainstorm Cell Theraputc has 3 upcoming scheduled events. The next event, "Warrant expiration", is scheduled for February 13, 2031 (in 1550 days). All of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the BCLI stock price.

Short Interest History

Last 12 Months

Short interest in Brainstorm Cell Theraputc (BCLI) currently stands at 60.6 thousand shares, up 77.0% from the previous reporting period, representing 0.6% of the float. Since November 2025, short interest has decreased by 77.8%.

Days to Cover History

Last 12 Months

Days to cover for Brainstorm Cell Theraputc (BCLI) currently stands at 2.0 days, up 36.7% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 71.5%. Across the settlements charted above, it has ranged from 1.0 to 8.4 days.

BCLI Company Profile & Sector Positioning

Brainstorm Cell Theraputc (BCLI) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing BCLI often look at related companies in the same sector, including Lobe Sciences Ltd (LOBEF), Pharmala Biotech Holding Inc (MDXXF), Synlogic Inc (SYBX), Onco-Innovations Ltd (ONNVF), and Inhibitor Theraptics Inc (INTI). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate BCLI's relative position within its industry.

Frequently Asked Questions

The current stock price of Brainstorm Cell Theraputc (BCLI) is $0.9500 as of November 16, 2026.

The market cap of Brainstorm Cell Theraputc (BCLI) is approximately $10.5M. Learn more about what market capitalization means .

The diluted earnings per share (EPS) of Brainstorm Cell Theraputc (BCLI) is -$1.11 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The current ratio of Brainstorm Cell Theraputc (BCLI), current assets divided by current liabilities, was 0.03 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

BrainStorm Cell Therapeutics Inc. focuses on developing autologous adult stem cell therapies for debilitating neurodegenerative diseases. Its proprietary NurOwn platform uses mesenchymal stem cells to produce neurotrophic factor-secreting cells designed to modulate neuroinflammation and promote neuroprotection.

NurOwn is BrainStorm’s lead investigational therapy based on autologous MSC-NTF cells derived from a patient’s own bone marrow mesenchymal stem cells. The company states that these cells are grown under patented conditions to secrete high levels of neurotrophic factors and immunomodulatory cytokines, with the goal of slowing or stabilizing disease progression in neurodegenerative disorders.

BrainStorm identifies amyotrophic lateral sclerosis (ALS) as the lead indication for NurOwn, with Orphan Drug designation from both the FDA and EMA. The company also reports a completed Phase 2 open-label multicenter trial of MSC-NTF cells in progressive multiple sclerosis.

The company reports that it has completed a Phase 3 trial in ALS (NCT03280056) and is preparing a Phase 3b ENDURANCE trial under a Special Protocol Assessment agreement with the FDA. The planned Phase 3b study is designed to enroll approximately 200 early-stage ALS participants and to generate confirmatory data to support a potential Biologics License Application.

Yes. BrainStorm states that NurOwn has received Orphan Drug designation for ALS from the U.S. Food and Drug Administration and the European Medicines Agency.

In a June 16, 2025 press release, BrainStorm reports survival data from 10 ALS participants in its Expanded Access Program, noting that 9 of 10 survived more than five years from symptom onset and that the median survival was 6.8 years. The company states that such outcomes are unlikely to be due to chance alone when compared with published ALS survival estimates.

A Form 25 filed on October 9, 2025 documents the removal of BrainStorm Cell Therapeutics Inc.’s common stock from listing and registration on Nasdaq. Subsequent company disclosures describe BCLI as quoted on the OTCQB Venture Market.

BrainStorm has announced a Letter of Intent with Minaris Advanced Therapies to manufacture NurOwn for an upcoming clinical trial, including technology transfer to a Minaris facility in Allendale, New Jersey. The company also refers to a collaboration with Pluri Inc. in Israel to contribute to production of clinical trial material.

Yes. In addition to its ALS program, BrainStorm reports a completed Phase 2 open-label multicenter trial of MSC-NTF cells in progressive multiple sclerosis and is advancing a proprietary allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids.

BrainStorm highlights ongoing engagement with the FDA through an IND amendment, a Special Protocol Assessment for the planned Phase 3b trial, and acknowledgment of a Citizen Petition submitted by ALS community representatives requesting renewed review of NurOwn data. The company also notes active interaction with clinicians and advocacy groups.